Sofosbuvir-based therapy cures hepatitis C virus infection after prior treatment failures in a patient with concurrent lymphoma

Journal of Clinical Virology

Volumn 69, Issue , 2015, Pages 74-77

  Romagnoli, Dante ^a   Marrazzo, Alessandra ^a   Ballestri, Stefano ^b   Lonardo, Amedeo ^a   Bertolotti, Marco ^a  

^a Gastrointestinal Endoscopy Unit   (Italy)

^b Pavullo Hospital   (Italy)

Author keywords

B cell non Hodgkin's lymphoma; Difficult to treat; Direct acting antiviral agent; Hepatitis C virus; Sofosbuvir

Indexed keywords

AMINOTRANSFERASE; ASUNAPREVIR; BENDAMUSTINE; DACLATASVIR; GABAPENTIN; IBRITUMOMAB TIUXETAN; NONSTRUCTURAL PROTEIN 5A INHIBITOR; PEGINTERFERON ALPHA2A; PROTEINASE INHIBITOR; RIBAVIRIN; RITUXIMAB; SOFOSBUVIR; TAPENTADOL; VIRUS RNA; ANTIVIRUS AGENT;

ADULT; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CASE REPORT; DRUG DOSE INCREASE; DRUG TREATMENT FAILURE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; MALE; NEUROPATHIC PAIN; NONHODGKIN LYMPHOMA; NONHUMAN; PANCYTOPENIA; PARESTHESIA; PRIORITY JOURNAL; SIDE EFFECT; VIRUS LOAD; COMBINATION DRUG THERAPY; COMPLICATION; DRUG EFFECTS; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; PATHOGENICITY; RECURRENT DISEASE; TIME FACTOR; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR RECURRENCE; VIROLOGY;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RECURRENCE; RIBAVIRIN; SOFOSBUVIR; TIME FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84937865159     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2015.05.023     Document Type: Article

References (14)

1. Adinolfi L.E., Zampino R., Restivo L., Lonardo A., Guerrera B., Marrone A., et al. Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanisms. World J. Gastroenterol. 2014, 20:3410-3417.
2. Cacoub P., Gragnani L., Comarmonda C., Zignego A.L. Extrahepatic manifestations of chronic hepatitis C virus infection. Dig. Liver Dis. 2014, 46:S165-S173.
3. Peveling-Oberhag J., Aracaini L., Mansmann M.L., Zeuzem S.J.T. Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management. J. Hepatol. 2013, 59:160-177.
4. Kawamura Y., Ikeda K., Arase Y., Yatsuji H., Sezaki H., Hosaka T., et al. Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C. Am. J. Med. 2007, 120:1034-1041.
5. Lebovics E., Czobor K. Screening, diagnosis, treatment, and management of hepatitis C: a novel, comprehensive, online resource center for primary care providers and specialists. Am. J. Med. 2014, 127:e11-4.
6. European Association for the Study of the Liver EASL clinical practice guidelines: management of hepatitis C virus infection. J. Hepatol. 2014, 60:392-420.
7. Everson G., Sims K., Rodriguez-Torres M., Hezode C., Lawitz E., Bourliere M., et al. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naïve patients with HCV genotype 1 infection. Gastroenterology 2014, 146:420-429.
8. Suzuki Y., Ikeda K., Suzuki F., Toyota J., Karino Y., Chayama K., et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J. Hepatol. 2013, 58:655-662.
9. Caviglia G.P., Sciacca C., Abate M.L., Olivero A., Rosso C., Touscoz G.A., et al. Chronic hepatitis C virus infection and lymphoproliferative disorders: mixed cryoglobulinemia syndrome, monoclonal gammopathy of undetermined significance, and B-cell non-Hodgkin. J. Gastroenterol. Hepatol. 2015, 30:742-747.
10. Strader D., Wright T., Thomas D.L., Seeff L.B. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004, 39:1147-1171.
11. Merck Sharp and Dohme Ltd. VICTRELIS (boceprevir) Summary of Product Characteristics, July 2011, Available at: (accessed 05. 15.). http://www.medicines.org.uk/EMC/medicine/24768/SPC/Victrelis+200+mg+hard+capsules/.
12. Janssen-Cilag Ltd. INCIVEK (telaprevir), Summary of Product Characteristics, September 2011, Available at: (accessed 05.15.). http://www.medicines.org.uk/EMC/medicine/25038/SPC/INCIVO+375+mg+film+coated+tablets/.
13. Lawitz E., Poordad F.F., Pang P.S., Hyland R.H., Ding X., Mo H., et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 2014, 383:515-523.
14. Gilead Sciences EAME, SOVALDI (sofosbuvir). Summary of Product Characteristics, July 2014, Available at: (accessed 05. 15.). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002798/WC500160597.pdf.